ZiQing, Pompe disease patient

Humanitarian Programs

Recognized as one of the industry's most generous in-kind givers, we work with local governments, patient associations, humanitarian organizations and others to provide free treatment to hundreds of qualified patients in need each year.

Serious diseases do not discriminate; they affect people from all walks of life and in all economic circumstances. We recognize our responsibility to the patient community does not end with simply developing effective therapies. We are committed to helping those therapies reach patients who qualify, to the best of our ability, regardless of their ability to pay.

Partnerships for humanitarian aid

In developing countries, government and private health coverage may be nonexistent, or barely able to address basic medical care. For patients who require specialized treatment, care can be financially and logistically beyond their means. Our Humanitarian Programs have long provided several of our therapies for free to people who qualify in these situations, by managing the process ourselves and partnering with humanitarian organizations. We rely on our organizational partners—including Project HOPE, ANERA, Direct Relief, the World Federation of Hemophilia Humanitarian Aid Program, and others – for their local expertise and relationships, which help us support patients and navigate the challenges of reaching them.

Even in countries with established health systems, patients can still face delayed or limited coverage, reimbursement difficulties, or other circumstances that prevent their access to treatment. For such cases, our Humanitarian Programs provide our therapies free of charge to many qualified patients, while also working with governments and other local entities to help identify sustainable, long-term financial resources for treatment.

Suyog, Gaucher disease patient
Learn more about our humanitarian partners
We have long been an industry leader in developing support programs and services to help patients obtain access to our treatments.

Helping patients around the world

Within our first year of having a commercial product in 1991, patients in the United States received access to free therapy. Since then, our humanitarian efforts have evolved and expanded to support five different lysosomal storage disorder (LSD) communities around the world and we’ve since broadened our program to include hemophilia patients.

The number of people living with LSDs is small—in the thousands or tens of thousands of people around the world. The number of LSD patients who receive free therapy through our Humanitarian programs often represents a significant percentage of the total population of people living with these diseases. To date, more than 750 LSD patients currently receive free therapy through our program. We have served more than 3,000 patients in 90+ countries since the program began, more than 300 of which have received free therapy for 10+ years.

Transforming humanitarian aid in hemophilia

We are committed to help transform the treatment of hemophilia in the developing world, where the vast majority of people with hemophilia have limited or no access to diagnosis and treatment and often don’t survive to adulthood due to lack of treatment. Together with Sobi™, we have pledged the single largest donation of hemophilia factor therapy in history.

In 2014, Sobi and Bioverativ, now part of Sanofi Genzyme, pledged to donate up to one billion IUs of factor over 10 years, including up to 500 million IUs to the World Federation of Hemophilia Humanitarian (WFH) Aid Program over a period of up to five years.

Suyog, Gaucher disease patient
Impactful donations
Since donations through the WFH program began in 2015, the impact has been far-reaching:

Our donation is an important first step toward providing those most in need with a predictable and sustainable supply of hemophilia therapy to transform the way care is delivered in these countries.

Our programs

Today our Humanitarian Programs are meeting the needs of patients on six continents and include:

  • International Charitable Access Program
  • Charitable Access Program (U.S.)
  • Gaucher Initiative (Egypt)
  • India Charitable Access Program (India)
  • China Charitable Access Program (China)
Samantha, Multiple Sclerosis patient
Reaching out to patients
We have long been an industry leader in developing support programs and services to help patients obtain access to our treatments.
Contact the Sanofi Genzyme U.S Charitable Access Program

Send us a message through our online form.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies.